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ABSTRACT 
Effective infection prevention and control hospital program is essential for prevention hospital 
associated infections (HAIs). Central line-associated bloodstream infection (CLABSI) is one of the 
major threating patients in intensive care units (ICUs).  However, CLABSIs can be prevented through 
proper prevention measures and guidelines information resources are free available in many national 
and international professional health agencies.  
Methicillin resistant Staphylococcus aureus (MRSA) is a major bacterial agent that causing 
community-and-hospital associated (CA/HA) infections and related to significant morbidity and 
mortality rates worldwide. Shigellosis is a highly infectious disease threating public health, especially 
with Shigella sonnei species in developed and developing countries. These two microorganisms have 
ability to develop resistance to many available antimicrobial agents and consequence successfully 
cloned and distributed globally.  
In 2011, the annual risk assessment of King Abdul Aziz Specialist hospital in Taif of Saudi Arabia has 
reported high incidence rate of CLABSI and the characteristic susceptibility patterns of community-
associated methicillin resistant Staphylococcus aureus (CA-MRSA) infections is different from the 
other locality in Saudi Arabia (data not published).  
High-resolution melting (HRM) has been used for MRSA spa typing in clinical diagnostic 
laboratories for epidemiological purposes as accurate, rapid and cost effective scheme method. Rotor 
gene 6000-system is excellent fully equipped for real-time amplification for HRMA. It is possible to 
introduce a hypothesis of HRM is accrete and rapid of MRSA spa-typing and S. sonnei genotyping 
method for epidemiological purposes. 
The hospital CLABSI prevention project was analyzed and extended to assess the susceptibility 
pattern, genotyping and virulence gene detection of MRSA infections in Saudi Arabia. Also, we tested 
the hypothesis of HRM genotyping by evaluating HRM of MRSA spa typing and identification of S. 
sonnei lineages and sub lineages using Rotor gene 6000-system among globally collected samples.  
There was about 60% reduction of CLABSIs after implementation of Society for Healthcare 
Epidemiology of America/Infectious Diseases Society of America (SHEA/IDSA) practice guidelines. 
HRM can distinguishable identification of MRSA spa types as well as S. sonnei lineages and sub 
lineages. Most of MRSA spa types were unambiguously typed. All S. sonnei lineages and sub 
lineages were identified using HRM real-time PCR. Also, the reproducibility was assessed and results 
revealed the same. We observed high prevalence of panton valentine leukocidine (PVL) positive 
related to hospital associated MRSA infections (HA-MRSA) is Saudi Arabia.  
The basic SHEA/IDSA practice recommendation is an effective prevention model for the reduction of 
CLABSI in the ICU. HRM-based is reproducible, simple, rapid and cost-effective for spa-typing and 
S. sonnei genotyping method. Emerging multi drug resistance S. aureus strains with PVL gene 
circulating within hospitals alarms the urgent need for continuous active surveillance and 
implementation prevention measures.   
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1 INTRODUCTION 
Effective infection prevention and control programmes in hospitals are essential to reduce and/or 
control infection risk factors and to prevent infections whenever possible. These require involvement 
by all staff members, patients, family members, students and visitors in order to maintain a healthy 
and safe environment. Healthcare-associated infections (HAIs) are the most adverse event threatening 
hospital patient safety worldwide. Many factors contribute to the risk of hospital-acquired infections, 
including inadequate hand hygiene compliance, poor infrastructure, understaffing, overcrowding, 
inappropriate invasive devices and inappropriate antimicrobial management [1].  
1.1 CENTRAL LINE-ASSOCIATED BLOODSTREAM INFECTION  
Central line-associated bloodstream infection (CLABSI) is responsible for increased morbidity, 
mortality, extended duration of hospital stay and excess healthcare costs in intensive care units (ICUs) 
world-wide [2]. International Nosocomial Infection Control Consortium (INICC)  is a multinational 
research network established to control and reduce HAIs at international level. It has reported that the 
incidence rate of CLABSI in ICUs in developing countries is three-fold higher than that in the United 
States [3]. CLABSI can be prevented through proper prevention measures, for which guidelines and 
information resources are freely available from many national and international professional health 
agencies. These include INICC, World Health Organization (WHO),  European Centre for Disease 
Prevention and Control (ECDC), US Center for Disease Control and Prevention (CDC), Infectious 
Diseases Society of America (IDSA) and  Society for Healthcare Epidemiology of America (SHEA). 
In the United States, the National Healthcare System Network (NHSN) was established in 2005 to 
collaborate with CDC on creation of infection surveillance systems using standardised methods and to 
categorise all infections using standard CDC definitions that include laboratory and clinical criteria. 
The CDC/NHSN system is now the most commonly used system for inter-hospital comparison and 
for identifying any future improvements required for patient safety. There is variation between 
countries in the CLABSI rates reported by CDC/NHSN and INICC, probably due to inadequate 
compliance with infection control guidelines, low compliance with hand hygiene and a lack of 
administrative and financial support [4].  
In Saudi Arabia, there are very limited data available on HAIs, especially CLABSI [5, 6]. 
However, comprehensive strategies to prevent CLABSIs in acute care hospitals have been formulated, 
e.g. by SHEA and IDSA [7]. Each recommendation is based on scientific evidence and includes 
administrative and financial guidelines that are measurable and easy to implement. Therefore these 
recommendations could be used to develop CLABSI prevention models for acute care hospitals in 
Saudi Arabia and elsewhere. 
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1.1 BASIC SHEA/IDSA PRACTICES FOR PREVENTION OF CLABSI IN ACUTE 
CARE HOSPITALS 
The SHEA/IDSA basic recommendations on practices to prevent CLABSI in acute care hospitals are 
summarised in Table 1 [7]. 
Table 1: Basic SHEA/IDSA practice recommendations for prevention of CLABSI in acute care 
hospitals 
 
Steps Recommendations 
Before insertion 
of central line 
Educate healthcare personnel involved in the insertion, care and maintenance 
of central venous catheters (CVC) about CLABSI prevention (A-II) 
At insertion 
1. Avoid using the femoral vein for central venous access in adult patients (A-I) 
2. Use maximum sterile barrier precautions during CVC insertion (A-I) 
3. Use chlorhexidine-based antiseptic for skin preparation in patients older than 
2 months of age (A-I) 
4. Use a catheter checklist to ensure adherence to infection prevention practices 
at the time of CVC insertion (B-II) 
5. Perform hand hygiene before catheter insertion or manipulation (B-II) 
6. Use all-inclusive catheter cart or kit (B-II) 
After insertion 
1. For non-tunnelled CVCs in adults and adolescents, change transparent 
dressing and perform site care with a chlorhexidine-based antiseptic every 5-7 
days or more frequently if the dressing is soiled, loose or damp; change gauze 
dressings every 2 days or more frequently if the dressing is soiled, loose or 
damp (A-I) 
2. Use antimicrobial ointment for haemodialysis catheter insertion sites (A-I) 
3. Replace administration sets not used for blood, blood products or lipids at 
intervals not longer than 96 hours (A-II) 
4. Remove non-essential catheters (A-III) 
5. Perform surveillance for CLABSI (B-II) 
6. Disinfect catheter hubs, needless connectors and injection ports before 
accessing the catheter (B-II) 
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The scientifically-based evidence for the SHEA/IDSA basic recommendations, according to criteria 
grading the strength of the recommendation and quality of evidence, are described in Table 2 [8].   
Table 2: Strength category (A-C) of individual SHEA/IDSA practice recommendations and quality of 
evidence (grade I-III) 
Category/grade Definition 
Strength of recommendation 
A 
B 
C 
 
Good evidence to support a recommendation  
Moderate evidence to support a recommendation 
Poor evidence to support a recommendation  
Quality of evidence 
I 
 
II 
 
 
 
 
III 
 
Evidence from >1 properly randomized, controlled trial 
 
Evidence from >1 well-designed clinical trial, without 
randomisation; from cohort or case-control analytical studies 
(preferably from >1 centre); from multiple time series; or from 
dramatic uncontrolled experiments  
 
Evidence from opinions of respected authorities, based on 
clinical experience, descriptive studies, or reports from expert 
committees 
Note: Adopted from the Canadian Task Force on Periodic Health Examination [8].  
1.2 STAPHYLOCOCCUS AUREUS  
Staphylococci are facultative anaerobic, Gram-positive spherical shaped bacteria that resemble 
clusters of grapes [9]. Historically, Staphylococcus aureus has had the ability to develop resistance to 
many available antimicrobial agents since 1940s to present. Penicillin was introduced for medical 
treatment in the 1940s, but S. aureus has developed resistance to beta-lactams. In 1960, semi-synthetic 
penicillin (methicillin) was introduced, but the organism soon developed resistance and the first case 
of methicillin-resistant Staphylococcus aureus (MRSA) was reported in 1961 [10]. The resistance of 
S. aureus to methicillin is caused by the presence of the mecA gene, located within a mec operon 
carried by transferrable chromosome staphylococcal cassette chromosome mec (SCCmec), encoding 
penicillin-binding protein 2a, which has a low affinity for all beta-lactam antibiotics [11].  
Staphylococcus aureus infections are a major cause of community-acquired (CA-) and hospital-
acquired (HA-) infections and are associated with significant morbidity and mortality rates. In 1999, 
NHSN reported that 52.3% of nosocomial infections occurring in ICUs were due to MRSA [12]. 
HAIs caused by multidrug-resistance have become a serious public health problem, especially in 
intensive care units (ICUs) due to patients’ existing condition, impaired immunity and exposure to 
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many invasive devices and antibiotic treatments, leading to increasing cost, morbidity and mortality 
[13-15]. Infections with CA-MRSA in patients with no contact with the hospital environment have 
been described worldwide [16-19]. Exposure of CA-MRSA strains to the selective pressure of 
antibiotics used in hospitals has the potential for selection of expanded antibiotic resistance profiles in 
the pathogen. Consequently, constant re-introduction of MRSA into hospitals from the community 
reservoir could significantly hamper infection control efforts [18, 20]. CA-MRSA strains are 
polyclonal, with an epidemiological association between clone type and geographical origin, whereas 
HA-MRSA infections are caused by a limited number of clones [18, 21, 22]. 
The rate of MRSA infection ranges from 12% to 49%, with variations in susceptibility pattern 
profiles, but there are very limited data on the prevalence of different genotypes in Saudi Arabia [23-
26]. A systemic review and meta-analysis of the prevalence of MRSA in the Kingdom of Saudi 
Arabia, based on 26 articles published between 2002 and 2012, revealed variation in the prevalence 
and antimicrobial susceptibility in patients, but also very limited data on genotyping and virulence 
gene detection [27]. Panton-valentine leukocidine-positive Staphylococcus aureus causes recurring 
skin and soft tissue infections. Recently, a molecular characterisation study on MRSA infections in 
Saudi Arabia showed a high diversity clonal complex encoding for PVL and carrying resistance 
markers in CA-MRSA strains [28]. Vancomycin is the drug of choice for therapy for MRSA 
infections. However, several countries have reported vancomycin-resistant S. aureus (VRSA) [29]. 
There are two mechanisms of glycopeptide resistance in S. aureus. The first is associated with a 
thickened cell wall [29] and the second type is acquisition of the vanA operon, carried by transposon 
Tn1546, resulting in high-level resistance [30, 31].  
1.3 MOLECULAR TYPING OF MRSA 
Phenotyping systems, such as serotype, biotype, phage type or antibiogram, have been used for many 
years. Moreover, methods allowing genotyping at molecular level provide the ability to discriminate 
types of bacteria species and result in high quality, accurate and reproducible data that can be shared 
globally using software. However, time demands and cost are challenges in application of molecular 
typing. SCCmec typing has been applied in epidemiological studies to distinguish MRSA strains or to 
define an MRSA clone in combination with the genotype of methicillin-susceptible S. aureus (MSSA) 
strains in which an SCCmec element is integrated. SCCmec elements consist of: (i) mec complex, 
composed of a mecA operon, (ii) ccr gene complex, composed of cassette chromosome recombinase 
(ccr) gene(s) and (iii) three regions bordering the ccr and mec complexes, designated as joining (J) 
regions. SCCmec element typing is defined by a combination of the type of ccr gene complex and the 
class of mec gene complex. Eleven SCCmec types have been described to date (www.sccmec.org). 
Recent work by the International Working Group on the Classification of Staphylococcal Cassette 
Chromosome (SCC) Elements (IWG-SCC) clarified the classification of the major SCCmec element 
types, but there is still a need for clarification regarding naming of the SCCmec variants and the 
accuracy of this typing for epidemiological purposes [11]. Pulsed-field gel electrophoresis (PFGE) is 
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considered the gold standard among molecular typing methods for a variety of clinically important 
bacteria, including MRSA [32]. The method has excellent discriminatory power, is inexpensive, has 
intra-laboratory reproducibility, is a standardised method and is suitable for short-term 
epidemiological studies. Unfortunately, the method is also time-consuming, labour-intensive and 
needs experts to interpret the results, especially with bands nearly identical in size. Multi-locus 
sequence typing (MLST) is a very popular tool for global epidemiology. It is based on sequencing 
DNA fragments of seven housekeeping gene of S. aureus (arcC, aroE, glpF, gmk, pta, tpi and yqiL) 
defined as a sequence type number (ST). The STs are grouped into a clonal complex [3] based on their 
similarity for six of seven shared alleles, as defined by eBURST (http://eburst.mlst.net) [33]. The tool 
is excellent to delineate clusters of closely related strains. Limitations of MLST tool are that it is not 
suitable for characterising differences in strains within outbreak, cost and time consumed. Protein A 
gene typing is the most widely used method for S. aureus genotyping. The polymorphic X region 
consists of a variable number of 24-bp repeats. These repeats are assigned a numerical code and the 
Staphylococcus protein A gene (spa) type is deduced from the order of specific repeats 
(spaServer.ridom.de). The diversity of the short sequence repeats in a conserved region is suitable for 
discrimination in outbreak investigation and useful in investigating both the local and global 
epidemiology of S. aureus [32, 34-39]. The complexity and the high cost of polymerase chain reaction 
(PCR) sequencing analysis are limitations to performing genotyping in developing countries. 
Recently, high-resolution melting (HRM)-based spa typing has been described as an accurate, rapid 
and cost-effective method for genotyping of MRSA isolates locally [40, 41].  
1.4 HIGH-RESOLUTION MELTING  
High-resolution melting is the characteristic of a targeted PCR product (amplicon) melting profile 
resulting from gradually increasing melting temperature (Tm) by very small increments in the 
presence of high-saturating DNA binding dye. As the temperature of the solution is increased, the 
specific sequence of the amplicon determines the melting behaviour [42]. In general, short amplicons 
of about 38 to 218 bp in length allow good discrimination to study the pattern of single nucleotide 
polymorphisms (SNPs) [43, 44]. Analysis based on HRM has been used in different clinical 
laboratory applications such as detection of the alpha-thalassemia-1 Southeast Asian allele [45], 
mutation detection in fibroblast growth factor receptor 3 gene [46], screening HLA identity between 
individuals as a possible alternative to current molecular and serological HLA typing [47], influenza A 
subtypes [48], herpes simplex virus (HSV) typing [49], identification of many different bacterial 
isolates [50], differentiation of Mycobacteria species [51] and S. aureus genotyping [40, 41]. The 
LightCycler® Nano system for HRM analysis is fast, highly sensitive and produces reproducible 
results for qualitative and quantitative detection of nucleic acids, melting curve analysis, SNP 
genotyping and mutation scanning. The software has no licence restrictions 
(www.lifescience.roche.com/shop/products/lightcycler-nano-instrument). A study by Chen et al. [41] 
demonstrated the robustness and reliability of HRM-based real-time PCR for MRSA spa typing using 
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the LightCycler® Nano system. Thus HRM spa typing can be applied in clinical diagnostic 
laboratories for epidemiological analysis and infection control of MRSA [41]. The Rotor-Gene 6000 
system enables real-time amplification for HRM analysis, with the rotary design giving great 
advantages in terms of thermal and equilibration time uniformity. To ensure accuracy, the Rotor-Gene 
6000 system uses an Optical Temperature Verification (OTV™) rotor that automates verification 
testing. Each test takes only minutes and can be repeated at any time and as often as required. The 
proprietary software has the ability to calculate the efficiency of individual amplification reactions and 
also has biostatistics and graphing capabilities. (www.biolabo.com/Real-Time-PCR-Detection-
System-Rotor-Gene-6000). Stephens et al. successfully discriminated 22 different MRSA spa types 
using the Rotor-Gene 6000 system [40]. HRM-based spa typing has been described as a rapid and 
cost-effective method for genotyping locally predominant isolates [40, 41].  
1.5 SHIGELLOSIS 
Shigellosis is an infectious diseases caused by various species of Shigella. The organism was 
discovered by Japanese microbiologist, Shiga, and later the genus given under his name. Shigellae are 
Gram-negative, rod-shaped, non-motile, and facultative anaerobic. They are highly infectious with 
incubation period of 12 hours up to 7 days. There are four Shigella species; Shigella dysenteriae, S. 
flexneri, S. boydii, and S. sonnei, which are classified into four sero-group A, B, C and D respectively, 
based on biomedical and serological differences. Clinical feature of the disease is characterized by 
diarrhea contain blood and mucus, vomiting, fever and abdominal cramps [52, 53]. The annual 
number of Shigella episodes throughout the world was estimated to be 164.7 million, of which 163.2 
million were in developing countries and 1.5 million in industrialized countries. The incidence rate 
varies according to age, geographical distribution, and local human development index (HDI). In 
developing countries, S. flexneri is the most commonly detected strain followed by S. sonnei strains. S. 
dysenteriae and S. boydii occur equally frequently. In contrast, S. sonnei is the most common 
serogroup found in industrialized countries followed by S. flexneri, S. boydii and S. dysenteriae. The 
variation incidence refers to different health infrastructure, surveillance system and laboratory 
diagnosis facilities between developing and industrial countries [54]. Sulfonamides, tetracycline, 
ampicillin, trimethoprim-sulfamethoxazole, nalidixic acid, and pivmecillinam have been used as first-
line antimicrobial drugs in many parts of the world [55]. However, Shigella has demonstrated 
extraordinary prowess in acquiring plasmid-encoded resistance to many antimicrobial agents. There 
are also geographic differences in the resistance rates suggesting the occurrence and spread of 
particular antimicrobial-resistant clones [54].  
1.6 SHIGELLA SONNEI 
Shigella sonnei has been predominantly responsible for dysentery in developed countries, but is now 
emerging as a problem in the developing world. In the United States [56], Shigella infections have not 
declined appreciably over the past 10 years and Shigella sonnei is responsible for the largest 
  7 
percentage of infections (75%), followed by S. flexneri (12%), S. boydii (0.8%) and S. dysenteriae 
(0.3%). The incidence rate of infection with S. sonnei decreased from 2008 to 2011, but increased in 
2012 [56]. Analysis following a recent outbreak in the United States demonstrated that the organism 
concerned displayed high minimum inhibitory concentrations (MICs) of azithromycin. Isolates were 
found to harbour macrolide resistance gene, mphA, located on a plasmid DNA [57].   
1.7 MOLECULAR TYPING OF S. SONNEI 
Shigella sonnei has only one serotype and is genetically homogeneous, but many genotyping methods 
have shown variations in the genome DNA and can distinguish between individual epidemic strains. 
Nevertheless, these methods may not be suitable for studying the variation and evolution of isolates 
within clone collected over long periods of time. One study found clear evidence of temporal variation 
over a 41-year period in frequency of a particular restriction site, which could be due to either periodic 
selection or random genetic drift within a clone of S. sonnei [58].  
To establish an accurate population, Holt et al. [59] sequenced the whole genome of 132 S. sonnei 
isolates collected globally between 1943 and 2008. They detected 10,111 chromosomal single 
nucleotide polymorphisms (SNPs) randomly distributed around the chromosome. Phylogenetic study 
methods showed a strong correlation between root-to-tip branch length and the known date of 
isolation, indicating rapid, clock-like evolution over 500 years. There is some rate variation between 
four lineages and, in addition, there are several geographically associated, multi-drug resistance clones 
that belong to specific lineage III [59]. Recently, Vartul S. et al. found that 97 SNPs were 
phylogenetically informative and can reliably discriminate the known S. sonnei lineages, a finding 
confirmed by sequencing analysis. Furthermore, six SNPs can define lineages/sub-lineages due to 
linkage association between 97 SNPs [60]. Several molecular typing methods, including MLST and 
PFGE, have been applied to S. sonnei in evolutionary and epidemiological studies. These methods are 
more labour-intensive, expensive, require special expertise and the results are difficult to interpret. An 
accurate, rapid and cost-effective typing scheme is urgently needed for active surveillance and 
epidemiological investigations. HRM typing is a highly sensitive, rapid and cost-effective option for 
such purposes. HRM data analysis does not require expert training and the method can be easily 
implemented in reference laboratories across the globe. It has been applied to Salmonella spp. studies 
[61]. HRM studies have also confirmed that the current global burden involves several geographically 
associated and multidrug-resistant clones that belong to a single lineage [59, 60].  
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2 AIM OF THE THESIS 
In 2011, the annual risk assessment of King Abdul Aziz Specialist hospital, Taif, Saudi Arabia, 
reported a high incidence of CLABSI and found that the characteristic susceptibility pattern of CA-
MRSA infections in the hospital was different from that at other locations (data not published). Based 
on these findings at the hospital, the aim of this thesis was to develop plans to reduce CLABSI, based 
on SHEA/IDSA practice guidelines, and to determine the epidemiological distribution of MRSA 
infections in Taif city. It was decided to use HRM as the genotyping method in laboratory diagnostics.  
The specific aims of the studies described in Papers I-IV were to: 
v Reduce central line-associated bloodstream infections in trauma intensive care units using 
basic SHEA/IDSA practice guidelines (Paper I) 
v Characterise MRSA infections in Taif city, Saudi Arabia (Paper II). 
v Evaluate the applicability of HRM MRSA spa typing (Paper III)  
v Introduce a new tool for HRM Shigella sonnei genotyping (Paper IV). 
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3 METHODOLOGICAL CONSIDERATIONS 
3.1 POPULATION (PAPER I) 
The work described in Paper I study was conducted from January 2011-December 2012 at the 23-bed 
trauma ICU at King Abdul Aziz Specialist Hospital in Taif (KAASH-Taif).  
3.2 CRITERIA OF CLABSI (PAPER I) 
 
Criteria of CLABI were defined according to NHSN guidelines [62], whereby: Laboratory-confirmed 
(LC) CLABSI is a primary bloodstream infection (BSI) in a patient who had a central line in place at 
the time of, or within 48 hours before, onset of BSI. LC-BSI must meet one of the following three 
criteria: 
1. Patient has a recognised pathogen cultured from one or more blood cultures and an organism 
cultured from blood in, not related to, an infection at another site. 
2. Patient has at least one of the following signs or symptoms:  
- fever (>38 oC), chills, hypotension  
- signs, symptoms and positive laboratory results are not related to an infection at another 
site 
- common skin contamination is cultured from two or more blood cultures drawn on 
separate occasions.  
3. Patient <1 year of age has at least one of the following signs or symptoms: 
- fever (>38 oC rectal), hypothermia (37 oC rectal), apnoea or bradycardia 
- signs, symptoms and positive laboratory results are not related to an infection at another 
site 
- common skin contamination is cultured from two or more blood cultures drawn on 
separate occasions.  
3.3 HAND HYGIENE OBSERVATION (PAPER I) 
Hand hygiene observation (HHO) was conducted using the WHO “My five moments” for hand 
hygiene recommendations. Calculations and statistical analyses were performed according to WHO 
recommendations [63, 64].    
3.4 BACTERIAL ISOLATES AND IDENTIFICATION  
For Paper I, bacterial identification and determination of susceptibility to a range of antimicrobials 
were carried out according to Clinical Laboratory Standards Institute [65] guidelines using the Vitek 
2system (BioMerieux, USA) [65, 66]. 
For Paper II, 28 clinical MRSA isolates were collected randomly from three referral hospitals in Taif 
between January and August 2011. Methicillin-resistant phenotype was confirmed according to 
British Society for Antimicrobial Chemotherapy [67] standards using the Vitek2 system (BioMerieux, 
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USA). An isolate is considered methicillin resistant when the minimum inhibitory concentration 
(MIC) breakpoint of oxacillin is  >2 mg/L and of cefoxitin >4 mg/L [67]. 
For Paper III, 50 clinical MRSA isolates collected between 2005 and 2012 were selected randomly 
from Scotland (n=22), Brazil (n=13), Sudan (n=3) and Saudi Arabia (n=12). All S. aureus isolates 
were identified as described previously; white colonies on blood agar plate, cocci bacterial shape and 
positive to Gram stain, catalase and coagulase [9]. Methicillin-resistant phenotype was determined in 
accordance with BSAC standards using the Vitek 2system (BioMerieux, USA). An isolate was 
considered MRSA when the MIC breakpoint of oxacillin was >2 mg/L and of cefoxitin >4 mg/L [67]. 
For Paper IV, 10 Shigella sonnei DNA samples (two for each lineage/sublineage) were provided by 
Institut Pasteur, France. However, lineage IV strain was not included in the study.  
3.5 ANTIMICROBIAL SUSCEPTIBILITY TESTING (PAPER II) 
The MIC of 17 antimicrobial agents, namely cefoxitin, chloramphenicol, ciprofloxacin, clindamycin, 
daptomycin, erythromycin, fusidic acid, gentamicin, linezolid, mupirocin, nitrofurantoin, oxacillin, 
penicillin, rifampicin, tetracycline, teicoplanin and vancomycin, was determined according to BSAC 
standards using the Vitek2 system (BioMerieux, USA). 
3.6 DNA EXTRACTION (PAPER II AND III) 
Genomic DNA was isolated from a 2-mL overnight culture with the DNeasy tissue kit (QIAGEN, 
Hilden, Germany), using lysostaphin (100 mg/L; Sigma, Taufkirchen, Germany). 
3.7 DETECTION OF PVL AND MECA GENES (PAPER II)  
 
A PCR was carried out for PVL and mecA gene amplification individually in two runs using a thermo 
cycler (Eppendorf, Hamburg, Germany) as described previously with modifications [68]. In brief, 20 
µL of final reaction mixture of each run containing 10 µL of 1X Taq master-mix reaction, 1 µL of 
each primer (100µM) (luk-PV-F: 5`-ATCATTAGGTAAAATGTCTGGACATGATCCA-3`, luk-
PV-R: 5`- GCATCAAGTGTATTGGATAGCAAAAGC-3`, and mecA-F: 5`-
GTAGAAATGACTGAACGTCCGATAA-3`, mecA-R: 5`- 
CCAATTCCACATTGTTTCGGTCTAA-3`) and 2 µL of the DNA (20 ng) template were used. PCR 
conditions were as follows: initial denaturation at 95 °C for 10 min, followed by 25 cycles of 
denaturation at 95 °C for 1 min, annealing at 74 °C for 1 min and extension at 72 °C for 1 min and a 
final extension step at 72 °C for 10 min. MRSA ATCC 35591 and DNase/RNase-free distilled water 
were included as positive and negative controls, respectively. For visualisation of the product, 10 µL 
of PCR amplicons were mixed with 1 µL of EzVision One loading dye (Amresco, Solon, OH, USA) 
and loaded into a 1.5% (wt/vol) agarose gel (Agarose ITM). Electrophoresis was carried out in 1X TAE 
buffer at 80 v for 50 minutes. A molecular weight marker 100-bp ladder (Promega, Madison, WI, 
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USA) was included on each gel. Bands were visualised using an Alpha Innotech UV imager 
(FluorChemTM).  
3.8 HA-MRSA AND CA-MRSA INFECTIONS CRITERIA (PAPER II) 
Identification of HA-MRSA and CA-MRSA infections was based on hospitalisation history and site 
of infection according to CDC/HNSN criteria [62]. An isolate was defined as HA-MRSA if the 
MRSA-positive specimen was obtained 2 days after hospital admission and met CDC site infection 
criteria. An isolate was defined as CA-MRSA if the MRSA-positive specimen was obtained within 48 
hours of admission, with no history of MRSA infection within a year as a risk of acquired MRSA.   
3.9 SPA AND MLST TYPING (PAPERS II AND III) 
The polymorphic regions of the spa gene and seven housekeeping genes (arc, aroE, glp, gmk, pta, tpi 
and yqiL) were amplified by PCR using the primers listed in Table 3, as described previously [34, 69]. 
All sequencing reactions were carried out using the ABI PRISM BigDye Terminator cycle sequencing 
ready reaction kit (Applied Biosystems, Foster City, California, USA). The sequence data were 
analysed in BioNumerics v.5.1 (Applied Maths). 
Table 3: List of primers used for genotyping  
Gene Forward 5`-3` Reverse 5`-3` 
Spa AGACGATCCTTCGGTGAGC GCTTTTGCAATGTCATTTACTG 
Arc TTGATTCACCAGCGCGTATTGTC  AGGTATCTGCTTCAATCAGCG  
aroE ATCGGAAATCCTATTTCACATTC  GGTGTTGTATTAATAACGATATC  
Glp CTAGGAACTGCAATCTTAATCC  TGGTAAAATCGCATGTCCAATTC  
Gmk ATCGTTTTATCGGGACCATC  TCATTAACTACAACGTAATCGTA  
Pta GTTAAAATCGTATTACCTGAAGG  GACCCTTTTGTTGAAAAGCTTAA  
Tpi TCGTTCATTCTGAACGTCGTGAA  TTTGCACCTTCTAACAATTGTAC  
Yqi CAGCATACAGGACACCTATTGGC  CGTTGAGGAATCGATACTGGAAC  
 
3.10 HRM ANALYSIS FOR SPA TYPING (PAPER III) 
The polymorphic X region of the spa gene was amplified in a Rotor-Gene 6000 instrument (Qiagen) 
using the SensiMix™ HRM kit (Bioline) as previously described [70]. In brief, a 20 µL PCR reaction 
was set up, containing 0.8 µL Eva-Green, 10 µL SensiMix™, 1 µL of each primer (100µM; 1095 
forward 5`-AGACGATCCTTCGGTGAGC-3` and 1517 reverse 5`-
GCTTTTGCAATGTCATTTACTG-3`) and 20 ng of the template DNA and programmed as follows: 
a hold at 95 °C for 10 min followed by 35 cycles of 95 °C for 20 s, 56 °C for 20 s and 72 °C for 22 s. 
The HRM of the amplicons was performed between 70 and 95 °C with a stepwise increase of 0.05 °C. 
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The melting temperatures (Tm) were determined by the negative derivative of decreased fluorescence 
over increased temperature (df/dt), using the proprietary software (version 1.7.34). The shapes of the 
melting curves were viewed with the same software. 
3.11 MULTIPLEX HRM ANALYSIS FOR SHIGELLA SONNEI GENOTYPING 
(PAPER IV)  
Primers were designed to amplify single nucleotide polymorphisms (SNPs) within kduD, deoA and 
emrA for typing the three main lineages in a first set run and to amplify SNPs within fdX and menF for 
typing sub-lineages in a second set run (Table 4). For the first run, a 20 µL multiplex real-time PCR 
mixture containing 10 µL  master mix (SensiMix with EvaGreen dye (Bioline)), 20 ng of template 
DNA and 2.5 µL of each primer of kduD, 1 µL of each primer of deoA and 1 µL of each primer of 
emrA was used. A similar reaction mix was used for each run, except that the primers used were 2 µL 
of each primer of fdX and 1 µL of each primer of menF. The multiplex PCR cycling was programmed 
as follows: the mixture was held at 95 °C for 10 min and then subjected to 35 cycles of 95 °C for 20 s, 
60 °C for 20 s and 72 °C for 22 s. The HRM was performed between 80 and 90 °C with a stepwise 
increase of 0.05 °C. The Tm was determined by the negative derivative of decreased fluorescence over 
increased temperature (df/dt), using the proprietary software (version 1.7.34).   
3.12 REPRODUCIBLE HRM GENOTYPING OF SHIGELLA SONNEI (PAPER IV) 
To assess the reproducibility, 10 samples of various lineages were randomly run blind under the same 
conditions. 
Table 4: Primers used for multiplex-HRM typing of Shigella sonnei  
Target of primers Direction Sequence 
kduD 
Forward 
Reverse 
5´-CGACGGCGAAACACTTTATC-3`  
5´-CGCGTATAAGAAGGCACACG-3`  
deoA 
Forward 
Reverse 
5´-GGAGATGCTTATCTCCGGCAAA-3`  
5´-AGTCGGTTGGGCCTTTT-3`  
emrA 
Forward 
Reverse 
5`-TGCCACCGAAGTACGTAACG-3`  
5`-CATCCACCCACATATTGGTG-3` 
fdX 
Forward 
Reverse 
5`-CAAAGCCTGGGACTGGA-3`  
5`-CATGGTTGATAGTGTAACGC-3`  
menF 
Forward 
Reverse 
5`- TATTCTCGCGCTGGTTTTTA-3`  
5`-GCTTTTCTTGGCTCTTCACC-3 
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4 RESULTS   
4.1 INSTITUTIONAL RISK ASSESSMENT (PAPER I) 
Observations revealed that there were three potential risk factors did not meet SHEA/IDSA basic 
recommendations: training of healthcare workers, removal of non-essential catheters and use of a 
catheter cart. All three risk factors were addressed. 
4.2 HAND HYGIENE OBSERVATION (PAPER I) 
The hand hygiene compliance rate ranged from 39% to 70% and the alcohol hand rub consumption 
rate was maintained at 43% during the study period.  
4.3 INCIDENCE RATE AND RATIO OF CLABSI P INTERVENTIONS (PAPER I) 
In 2011, there were 14 cases of CLABSI and the incidence rate was 3.87 per 1000 central line days 
with utilisation ratio of 0.53. In 2012, following implementation of basic SEHA/ISDA practice 
recommendations on hospital hygiene, the number of CLABSI cases was six and the incidence rate 
was 1.5 per 1000 central line days, with a utilisation ratio of 0.60. A summary of CLABSI cases, rate 
and ratio benchmarking to NHSN hospitals in 2011 and 2012 is presented in Table 5.  
Table 5: Incidence rate and ratio of CLABSI reported during the study period (2011-2012) at the 
study hospital compared with NHSN hospitals (DA Module 2010) 
Year Number of 
CLABSIs 
Device 
days 
Patient 
days 
Rate/1000 
device days 
Comparison 
with NHSN 
percentiles 
Ratio Comparison 
with NHSN 
percentiles 
2011 14 3.616 6.835 3.87 75 – 90 0.53 25 – 50 
2012 6 4.134 6.864 1.5 50 0.60 50 – 75 
 
4.4 IDENTIFICATION OF MICROORGANISMS CAUSING CLABSI  (PAPER I)  
Microorganisms identified as causing CLABSI are listed and their incidence is summarised in Table 
6. It was found that CLABSIs were caused predominantly by multidrug-resistant bacteria, namely; 
Klesiella pneumonia, Enterococcus faecalis and Acinetobacter baumannii. 
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Table 6: Type and incidence of microorganisms causing CLABSI during the study period 
Microorganisms 
Number of isolates per year 
2011 2012 
Klebsiella pneumonia 3 3 
Enterococcus faecalis 2 2 
Acinetobacter baumannii 2 1 
Enterobacter cloacae 2 0 
Escherichia coli  1 0 
Pseudomonas aeruginosa 1 0 
Methicillin resistant Staphylococcus aureus 1 0 
Proteus mirabilis 1 0 
Burkholderia spp 1 0 
Total 14 6 
 
4.5 SUSCEPTIBILITY PATTERN OF MRSA ISOLATES (PAPER II) 
All MRSA isolates proved to be susceptible to chloramphenicol, daptomycin, nitrofurantoin, 
teicoplanin, rifampicin and vancomycin. However, resistance rates varied as follows: fusidic acid 
(46%), tetracycline (39%), ciprofloxacin (36%), trimethoprim (28%), gentamicin (25%), clindamycin 
(21%), erythromycin (14%) and mupirocin (7%). Three strains demonstrated resistance to eight 
antimicrobial agents (ciprofloxacin, clindamycin, erythromycin, fusidic acid, gentamicin, tetracycline, 
trimethoprim and mupirocin).  
4.6 SPA AND MLS GENOTYPING OF MRSA ISOLATES (PAPER II) 
Twelve spa types were identified, including t4573 (21%) followed by t304 (18%) and t044, t267 and 
t363 (10% of each). Eight multi locus sequence types (MLSTs) were identified, with the majority 
being sequence type (ST) ST-22 (32%), followed by ST-80 and ST-97 (14%), ST-2882 (11%), ST-
241 (7%) and ST-239, ST-5 and ST-6 (3%). The t4573/ST-22 genotype was most prevalent in the 
hospital (46%).  
4.7 PVL AND MECA GENES DETECTION (PAPER II) 
All isolates tested positive for mecA gene. Thirteen MRSA isolates (46%) tested positive for PVL 
gene; 54% related to HA-MRSA infection and 46% to CA-MRSA infection. All t4573/ST22 strains 
were resistant to ciprofloxacin, harboured PVL gene and were related to surgical site infection, skin 
soft tissue infections and pneumonia (Table 7). 
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Table 7: Genotypes and susceptibility pattern of MRSA infections observed at KAASH-Taif, Saudi 
Arabia, 2012  
Spa-type (N) MLST (N) PVL (N) Resistant to  
t304 (5) 
2882 (3) -ve (3)  
6 (2) -ve (1)/ +ve (1) 
t311 (1) 5 (1) -ve (1) Cli 
t2770 (2) 
97 (5) 
-ve (2) / +ve (1) Fa 
t267 (3) -ve (2) Fa, Te, Gan 
t044 (3) 
80 (4) 
+ve (5) Fa, Te t131 (1) 
t037 (1) 239 (1) 
t4573 (6) 
22 (9) 
-ve (1)/ +ve (5) 
Cip 
Cip, Tr 
Cip, Cli, Tr, Gen, Ery 
t748 (1) +ve (1) Cip, Tr 
t5716 (1) 
-ve (2) 
Cli, Tr 
t223 (1) Tr, Te 
t363 (3) 241 (3) -ve (3) 
Cli, Fa, Cip, Tr, Te, Gen, Ery, Mu 
Cli, Fa, Cip, Tr, Te, Gen, Ery, Van 
Cli: clindamycin, Fa: fucidic acid, Cip: ciprofloxacin, Tr: trimethobrium, Te: tetracycline, Gen: 
gentamicin, Ery: erythromycin, Mu: muperocin 
4.8 HRM SPA TYPES IDENTIFICATION (PAPER III) 
Nineteen spa-types were identified among 50 clinical MRSA isolates. Spa type t037 was the prevalent 
type among Brazilian isolates (12/13) and Sudanese isolates (3/3).  Eight spa types were observed 
among 22 isolates from Scotland and nine spa types among 12 isolates from Saudi Arabia.  
Fifteen out of the 19 spa types detected each had a distinct melting temperature (Tm) that 
unambiguously assigned 44 isolates (Table 8, Figure 1). Both t008 and t2770, as well as t311 and t021 
spa types, shared the same Tm (80.3 and 81.0 °C, respectively) (Figure 2) 
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Table 8: HRM and spa sequences of MRSA isolates and frequencies in different countries 
 
*spa types in bold share the same melting temperature (Tm) with another spa type.  
 
 
 
 
 
 
 
HRMT Tm 
Spa-
type 
Repeat of spa type 
Si
ze-
bp 
CG
% 
Country (N. of spa 
types/total) 
1 79.4 t1544 07-22-34 72 44.4 Saudi Arabia (2/12) 
2 79.5 t344 09-02-16-13-34 12
0 
50 Scotland (5/22) 
3 79.7 t044 07-23-12-34-34-33-34 16
8 
41.7 Saudi Arabia (1/12) 
4 79.8 t131 07-23-12-34-33-34 14
4 
42.3 Saudi Arabia (1/12) 
5 80.2 t304 11-10-21-17-34-24-34-22-25 21
6 
43.5 Saudi Arabia (1/12) 
6 
80.3
* 
t2770 07-23-12-12-21-17-34-34-33-34 24
0 
42.5 Saudi Arabia (2/12) 
t008 11-19-12-21-17-34-24-34-22-25 24
0 
43.7 Scotland (1/22) 
7 80.4 t138 08-16-02-25-17-24 14
4 
45.1 Brazil (1/13) 
8 80.6 t037 15-12-16-02-25-17-24 16
8 
45.2
3 
Brazil (12/13) and 
Sudan (3/3) 9 80.7 t363 15-16-02-25-17-24 14
4 
45.8 Saudi Arabia (1/12) 
10 80.8 t1198
6 
04-44-33-31-31-12-34-16-12-25-22-34 28
5 
43.5 Saudi Arabia (1/12) 
11 80.9 t018 15-12-16-02-16-02-25-17-24-24-24 26
4 
44.8
6 
Scotland (6/19) 
12 
81.0
* 
t311 26-23-17-34-20-17-12-17-16 21
6 
44.9 Saudi Arabia (1/12) 
t021 15-12-16-02-16-02-25-17-24 21
6 
44.9 Scotland (2/22) 
13 81.2 t002 26-23-17-34-17-20-17-12-17-16 24
0 
45.4 Scotland (2/22) 
14 81.3 t4573 07-23-13-23-31-05-17-25-16-28 24
0 
45.0 Saudi Arabia (2/12) 
15 81.4 t020 26-23-31-29-17-31-29-17-25-17-25-16-28 31
2 
44.5 Scotland (1/22) 
16 81.8 t4291 26-23-23-13-23-31-29-17-31-29-17-25-16-25-16-28 36
0 
43.8 Scotland (1/22) 
17 81.9 t032 26-23-23-13-23-31-29-17-31-29-17-25-17-25-16-28 38
4 
45.0
5 
Scotland (4/22) 
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Figure 2: Melting curve shapes allowing assignment of spa types that shared the same melting 
temperature (Tm). (A) Characteristics of melting curve shapes for t2770 and t008, which had identical 
Tm = 80.3 °C. (B) Characteristics of melting curve shapes for f t021 and t311, which had identical Tm 
= 81.0 °C. 
4.9 HRM GENOTYPING OF SHIGELLA SONNEI (PAPER IV) 
The first set run separated lineages I, II and III with distinctive melting curves and the Tm of each 
allele was at least a half degree away from that of other alleles (Figure 3A). The second set run 
distinguished the sublineages IIIa, IIIb and IIIc with distinctive melting curves (Figure 3B). The Tm 
references for all alleles are summarised in Table 9.  
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Figure 3A: Multiplex-HRM curve of three single nucleotide polymorphisms (SNPs) in kduD, deoA 
and emrA, respectively (from left to right), which separate Shigella sonnei lineages I, II and III.   
 
 
 
 
 
 
Figure 3B: Multiplex-HRM curve of two single nucleotide polymorphisms (SNPs) in fdX  (left) and 
menF (right), which separate lineages IIIa, IIIb and IIIc. 
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Table 9: Summary of melting temperature (Tm) for each of the five single nucleotide polymorphisms 
(SNPs) used for multiplex-HRM analysis 
Lineages 
Tm (° C) (+/- 0.05) for: 
kduD deoA emrA fdX menF 
Mail lineages  
 
I 83.0 85.1 87.7 
II 82.5 84.8 87.7 
III 82.5 85.2 877.3 
Sub lineages 
 
IIIa 82.5 85.7 
IIIb 82.5 86.0 
IIIc 82.9 85.7 
 
4.10 REPRODUCIBLE HRM GENOTYPING OF SHIGELLA SONNEI (PAPER IV) 
A randomly selected 10 samples of different lineages revealed similar results, with +/-0.05 differences 
in Tm.  
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5 DISCUSSION 
CLABSI is an important cause of increased morbidity, mortality, increased duration of hospital stay 
and excess healthcare costs in ICUs [7]. In Saudi Arabia, very limited data on CLABSI in adult ICUs 
are available. The CLABSI incidence rate to percentile NHSN benchmarking detected in this thesis in 
2011 indicated a need to improve patient care practice in the trauma ICU in KAASH-Taif hospital. 
Therefore, it was decided to introduce a strategic plan to reduce CLABSI and deliver high quality 
performance, as well as patient safety.  
Basic SEHA/ISDA practice recommendations were chosen for this purpose due to their concise 
format and applicability in the hospital setting and their inclusion of measurable elements. There was 
a significant reduction in CLABSI after intervention implementing the SEHA/ISDA practice 
recommendations. However, the difference in the annual rate of incidence of CLABSI before and after 
resolving risk factors was not statistically significant due to low number of cases in the study period. 
Nevertheless, the incidence rates were maintained within the pooled mean in 2012 (Figure 4).  
It is recommended that device-associated infection rates and device utilisation ratios be examined 
together, so that preventive measures may be appropriately targeted [71]. The 90th percentile NHSN 
benchmarking of CLABSI incidence rate with the 50th percentile NHSN benchmarking of utilisation 
ratio indicated that prevention measures should be focused on before and during insertion of a central 
line. After the intervention period, CLABSI incidence declined to the 50th percentile of NHSN 
benchmarking and the utilisation ratio to a higher (75th) percentile of NHSN benchmarking, indicating 
staff training, catheter cart preparation and removing unnecessary central lines as important prevention 
measures.  
 
Figure 4: Incidence of CLABSI reported before and after implementation of SEHA/ISDA practice 
recommendations.  
2.2 
3.5 3.7 
5.6 
1.1 
2.3 
1.5 
0.9 
0 
1 
2 
3 
4 
5 
6 
1st 
Quarter 
2nd 
Quarter 
3rd 
Quarter 
4th 
Quarter 
1at 
Quarter 
2nd 
Quarter 
3rd 
Quarter 
4th 
Quarter 
In
ci
de
nc
e 
R
at
e/
10
00
 c
en
tr
al
-li
ne
 d
ay
s 
Study Period 
CLABSI incidence rates before and after interventions in ICU of 
KAASH-Taif, Saudi Arabia during the study period 
After intervention, 2012 Before intervention, 2011 
 24 
Lack of familiarity with practice guidelines by healthcare workers has been identified as a main 
barrier to the proper implementation of these guidelines. Alfonso et al. observed a significant 
reduction (35%) in CLABSI in ICUs after training interventions and noted that a programme of 
continual training is the first step toward achieving compliance with guidelines [72]. The use of a 
central line monitoring protocol in the study hospital ensured prompt removal of non-essential central 
line catheters. The method was easily reproducible, with positive feedback from healthcare workers. 
The introduction of a catheter cart and kit made it easy for staff to access and adhere to preventive 
measures during insertion of a central line catheter. Regular meetings with the CLABSI prevention 
team and ICU department were held, with dissemination of feedback to all stakeholders.  
However, despite regular reminders about the importance of hand hygiene, the compliance rates were 
variable (39-70%, average rate 56%) and with a low alcohol consumption rate of 43% (p=0.15). This 
is perhaps due to the fact that the ICU is a very busy care area. The significant reduction in CLABSI 
in the trauma ICU studied indicates the positive impact of addressing these three risk factors. 
However, it is clear that regular training programmes, particularly with respect to hand hygiene 
compliance, should be held regularly to maintain high performance in patient care services.  
 
The incidence rates and susceptibility patterns to antimicrobial agents are variable across geographical 
regions, due to many factors such as surveillance methods, economic status and use of antimicrobials. 
There is wide variation in the antimicrobial susceptibility pattern in Saudi Arabia. Rifampicin 
resistance has previously been observed in Al Khubar (76%), Qassem (60%), Taif and Riyadh (33%), 
Aseer (11%( and Makkah (6%), but not in Najran city [73-79]. Chloramphenicol resistance has been 
recorded  in Taif (30%) and Asser (1.5%) [74, 75].  Only one case of daptomycin resistance has been 
reported in Saudi Arabia, in Najran (9.4%) [77]. This variation can be assumed to be a reflection of 
differences in study design and surveillance method.  
Multidrug-resistant S. aureus has been reported in many hospitals world-wide but, to the best of my 
knowledge, this thesis is the first study to report multi-drug resistant MRSA with resistance to 
ciprofloxacin, clindamycin, erythromycin, fusidic acid, gentamicin, mupirocin, tetracycline and 
trimethoprim in Saudi Arabia.  
A diversity of spa and MLST types were identified in Taif, with t4573/ST-22 being the most prevalent 
in the hospital (21%). Similar diversity has been reported in Riyadh [79, 80].  
Interestingly, although t4573, harbouring PVL gene and resistant to ciprofloxacin, is common in Taif 
city (n=6, 21%), the strain has a very rare distribution worldwide and is not well characterised. One 
isolate has been reported in Saudi Arabia (Riyadh) [79], one in New Zealand [81] and two in Sweden 
(www.spaserver.ridom.de). One isolate of t037 was detected in Taif, but t037 is common in Riyadh 
(35%) and has a wide global distribution. This variation probably reflects the low sample collection in 
the present study.  
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Clonal complex (CC) 22 is the most common MLST type (n = 9, 32%) [28]. PVL-positive MRSA 
strains are associated with complicated infections; especially skin infections and necrotising 
pneumonia.  
High prevalence of the gene encoding PVL was noted in Taif city (46%) and tended to be more 
associated with HA-MRSA infection (62%) compared with CA-MRSA (39%). In contrast, Monecke 
et al. demonstrated high prevalence of PVL-positive (54%) samples in strains considered CA-MRSA 
in Riyadh [28]. This variation is most likely the result of the data and samples in this thesis being 
obtained from a hospital-based survey and not a population-based study.  
All ST80 strains detected here tested positive for PVL gene. Moreover, all ST80 strains tested positive 
for PVL gene. Similarly, PVL positivity has been detected in MRSA ST 80 genotype in many 
countries [82-88]. Although Bin Nejam and colleagues demonstrated that all MRSA ST80 Tunisian 
isolates were intermediately susceptible to fusidic acid [82], all of our MRSA ST-80 strains were 
resistant to fusidic acid. This variation probably reflects differences in antibiotic use between the 
countries. Fucidic acid is commonly used for local treatment and is one of the antimicrobial agents 
used for elimination of MRSA in hospitals in Saudi Arabia.  
The proportion of HA-MRSA infections (50%) was higher than that of CA-MRSA infections (25%) 
in this thesis. Similarly, Eed EM et al. observed in a recent study that HA-MRSA infections were 
more common than CA- MRSA infections in Taif [74]. However, the higher prevalence of HA-
MRSA compared with CA-MRSA in this thesis probably does not reflect the true values, because the 
data and samples were obtained from a hospital-based survey and not a population-based study.  
No correlation was found between positivity to PVL and CA/HA-MRSA infections. CA-MRSA has 
several molecular characteristics compared with HA-MRSA, for example SCCmec types V and IV 
usually produce PVL and are generally susceptible to non-β-lactam antibiotics [18, 89]. However, 
time-based definition of CA-MRSA with the recently changing epidemiology of MRSA infections 
may make it difficult to differentiate between CA-MRSA and HA-MRSA infections [18]. In this 
thesis, PVL-positive samples were observed in both CA-MRSA and HA-MRSA categories. Similarly, 
a previous study demonstrated that global CA-MRSA outbreaks could occur in the presence or 
absence of PVL gene [18]. It is possible that CA-MRSA category infections (SCCmecA types I, II or 
III) are transferred to, and colonise, patients or hospital environments and may cause hospital 
infections, thus becoming HA-MRSA category. Unfortunately, there were limitations to clarifying the 
epidemiology of MRSA infections in Taif city in the present thesis, for reasons including: no 
SCCmecA-typing, sample numbers were very low and the data were obtained by hospital-based 
surveillance.  
There were indications that there may be an association between MRSA ST-80 and PVL positivity, 
but not with susceptibility to antimicrobial agents.  More in-depth study of a larger number of clinical 
MRSA ST-80 samples is required to determine whether this is a genuine association or a chance 
observation in the small study group included in this thesis.   
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Regarding HRMT, this thesis successfully confirmed the reproducibility of HRM genotyping of 
MRSA spa typing. However, despite the difference in GC content between t008 and t2770 (43.7 
mol% and 41.5 mol%, respectively), these spa types shared the same Tm (80.3 °C; Figure 2A). 
Moreover, t021 and t311 could not be separated from each other, as they shared a Tm (81.0 °C) 
(Figure 2B), probably due to the fact that they have same 44.9 mol% of the GC content. These results 
are in agreement with Stephens et al. who could not separate two spa types from each other based on 
their Tm [40].  
It has been suggested that shape of the melting curves are also important in determining the spa types 
[40, 90, 91]. In this thesis, there were some minor variations in the shapes of melting curves between 
t008 and t2770, and between t021 & t311 (Figures 2A and B). These variations in the shape of melting 
curves were reproducible, but it is difficult for inexperienced users to confidently predict the correct 
spa types from these variations, which highlights the challenge in optimising HRM-based spa typing 
for the growing number of spa types of MRSA.  
Some discrepancies in Tm values between this study and previous investigations by Stephens et al. 
[40, 41]and Chen et al. [41] were observed and are summarised in Table 10. Stephens et al. used 
Platinum SYBR-Green qPCR Super Mix-UDG (Life Technologies) on a Rotor-Gene 6000 instrument 
(Qiagen), while a SensiMix™ HRM (Bioline) mix with Eva-Green dye on a Rotor-Gene 6000 
instrument (Qiagen) was used in this thesis. Chen et al. used LightCycler 480 HRM Master Mix 
containing ResoLight dye on a LightCyclerNano real-time PCR system (Roche) [41]. The Tm values 
both for t037 and t002 were relatively close between this study and the other two studies, suggesting 
that the same instrument might provide similar Tm values for a spa type and that minor variations may 
have been caused by different reaction mixes that contained different reporting dyes. More 
discrepancies in the Tm values between Stephens et al. and Chen et al. were observed for additional 
spa types. Therefore, different instruments and reagents (dye in the reaction mix) may result in 
discrepancies in the Tm values of a spa type. 
In this thesis, new tools for S. sonnei lineage genotyping using the multiplex HRM method were 
successfully introduced. To confirm the reproducibility, 10 samples of different lineages were run 
randomly in a blind experiment, which produced comparable results. Sequencing of five SNPs also 
independently verified the reliability of the Tm data, as shown in Table 11.  
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Table 10: Comparison of Tm values obtained in three independent studies  
Tm HRM-spa typing by 
Stephen et al, 2008 Chen et al, 2013 Present study, 2015 
79.4   
 
t1544 
79.5 t344 
79.6 t123  
79.7 t352, t065 * t044 
79.8 t186 t131 
80.0 t190  
80.1 
 80.2 t304 
80.3 t2770, t008 **, ^ 
80.4 t437 $ t138 
80.5   
80.6 t127, t008 * t037 # 
80.7 t019 $ t363 
80.8  t11986 
80.9 t037 #, t1155 * t018 ** 
81.0 t216  t311, t021 ^ 
81.1 t631  
81.2  t002 # 
81.3 t018 ** t4573 
81.4  t020 
81.5 
 81.6 t002 # 
81.7 
 
81.8 t4291 
81.9 t032 *** 
82.0 
 
82.1 t9469 
82.2 t202  
82.3 
 
t1081 
82.5 t9377 
82.6 t4677 
82.9 t701 
83.1 t437 $ 
83.2 t121 
83.3 t019 $ 
83.6 t037 # 
84.0 t032 *** 
84.1 t002 # 
84.3 t9970 
*Tm cannot distinguish spa types in Stephen et al. **Tm discrepancy of spa types between this thesis and 
Stephen et al. ***Tm discrepancy of spa type between this thesis and Chen et al. $Tm discrepancy of spa types 
between Stephen et al and Chen et al studies.  #Tm discrepancy in the three studies (text in bold).  
^Melting curve shape can distinguish spa types in this thesis.  
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Table 11. Single nucleotide polymorphisms (SNPs) used for multiplex-HRM Shigella sonnei typing 
Gene 
SNP 
position 
Nucleotide in: 
Ancestor Derived 
sequence 
Lineage I Lineage II Lineage 
IIIa 
Lineage 
IIIb 
Lineage 
IIIc 
kduD 3155111 T C G T T T T 
deoA 4803842 G A G A G G G 
emrA 2973337 T C C C T T T 
fdX 2760031 G A G G G A A 
menF 2455693 A G A A A A G 
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6 CONCLUSIONS 
• The basic SHEA/ISDA practice recommendations provide an effective prevention model for 
reduction of CLABSI in hospital ICUs   
• Multidrug-resistant Staphylococcus aureus strains with the PVL gene are circulating within 
hospitals in Saudi Arabia, highlighting an urgent need for continuous active surveillance and 
implementation of prevention measures.  
• High-resolution melting has good reliability as a method for MRSA spa typing and Shigella 
sonnei genotyping, providing accurate, rapid and cost-effective diagnosis for epidemiological 
purposes. The method can be performed in diagnostic laboratories locally and globally. 
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